Tanino T, Ogiso T, Iwaki M
Faculty of Pharmaceutical Sciences, Kinki University, Higashi-Osaka, Osaka, Japan.
Biol Pharm Bull. 1999 Mar;22(3):298-304. doi: 10.1248/bpb.22.298.
Inclusion complexes of phenytoin (DPH) with 6-O-alpha-D-glucosyl (G1)- and 6-O-alpha-D-maltosyl (G2)-beta-cyclodextrins (beta-CyDs) were prepared in a molecular mixing ratio of 1:1. The advantages of these preparations in terms of dissolution characteristics and the oral absorbency of DPH were evaluated in comparison with the known solid dispersions of polyvinylpyrrolidone K-30 and sodium deoxycholate (DC-Na). The results of a phase-solubility study indicated that G1- and G2-beta-CyDs provided higher solubility for DPH than 2-hydroxypropyl (HP)-beta-CyD. Irrespective of inclusion ability, the DPH/beta-CyD complexes allowed faster dissolution rates than those of the known dispersions in JP 1st and 2nd mediums. The dissolution behavior of the DPH/DC-Na dispersion was considerably different between the 1st and 2nd mediums. The complexation by the sugar-modified derivatives yielded a higher stability of dissolved DPH in the JP 2nd medium than that yielded by K-30 or DC-Na. The safe estimation of carriers themselves indicated that G1- and G2-bet-CyDs did not damage the small intestine, while 10 mM DC-Na showed some damage. Compared with the DPH/K-30 dispersion, the preparations with the sugar-modified beta-CyDs were more effective in enhancing the absorbability of DPH after oral administration. These results clearly suggest that complexation with G1- and G2-beta-CyDs are useful forms for the oral delivery of DPH. The advantage of these complexes is that they produce an increased level of DPH available for gastrointestinal absorption. Additionally, G2-beta-CyD is recommended as a safe and potent additive for DPH.
制备了苯妥英(DPH)与6 - O-α-D-葡萄糖基(G1)和6 - O-α-D-麦芽糖基(G2)-β-环糊精(β-CyDs)的包合物,分子混合比为1:1。与已知的聚乙烯吡咯烷酮K-30和脱氧胆酸钠(DC-Na)固体分散体相比,评估了这些制剂在DPH溶解特性和口服吸收方面的优势。相溶解度研究结果表明,G1-和G2-β-CyDs比2-羟丙基(HP)-β-CyD为DPH提供了更高的溶解度。无论包合能力如何,DPH/β-CyD复合物在日本药典第一和第二介质中的溶解速度都比已知分散体快。DPH/DC-Na分散体在第一和第二介质中的溶解行为有很大差异。糖修饰衍生物的络合作用在日本药典第二介质中产生的溶解态DPH稳定性高于K-30或DC-Na。对载体本身的安全性评估表明,G1-和G2-β-CyDs不会损伤小肠,而10 mM DC-Na显示有一定损伤。与DPH/K-30分散体相比,糖修饰β-CyDs制剂在口服给药后更有效地提高了DPH的吸收能力。这些结果清楚地表明,与G1-和G2-β-CyDs络合是DPH口服给药的有用形式。这些复合物的优点是它们能产生更高水平的可用于胃肠道吸收的DPH。此外,推荐G2-β-CyD作为DPH安全有效的添加剂。